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Conclusion: Salvage I-125-BT patients can be selected based 
on their disease free survival interval after primary therapy 
and the PSA-doubling time pre-salvage, ensuring sufficient 
biochemical control of >70% until three years. 
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Purpose or Objective: To report the incidence of second 
primary cancer ( SPC) after Iodine-125 brachytherapy for 
early prostate cancer in a single institution with an intense 
urological surveillance and to compare it with the cancer 
incidence in the Australian population 
 
Material and Methods: This retrospective, single-institution 
study included 889 patients treated with Iodine-125 
brachytherapy alone. All the patients had a baseline 
cystoscopy before the implant. Data were collected on all 
subsequent SPC diagnoses. SPC incidences were retrieved for 
all type of cancers and for cancers close to the radiation 
field. Interval since the implant was evaluated for potential 
association to the treatment. Standardized incidence ratios 
(SIRs) were calculated for all cancers and for bladder cancers 
and matched with the general population. The absolute 
excess risk (AER) was expressed in relation to 10000 persons-
years in the study. Kaplan-Meier analysis was used to 
determine the actuarial second malignancy and pelvic 
malignancy rates and the death from SPC and from any cause 
 
Results: Patients were followed for a median of 4.16 (0-12) 
years with 370 (42 %) patients having 5 years or more follow 
up. 62 % patients were older than 60 years. 61 patients (6.8%) 
subsequently developed a SPC with 12 pelvic malignancies : 8 
bladder and 4 rectal cancer. The 5- and 10- year cumulative 
incidences are 6.9% (95% Confidence Interval 5.0-9.4) and 
19% (95% CI 14-26) for any second malignancy, 1.3% (95%CI 
0.6-2.7) and 3.9% (95% CI 1.9-7.8) for any pelvic malignancy 
and 1% (95% CI 0.4-24) and 3.2% (1.4-7.1) for bladder cancer, 
respectively. The SIR was significantly higher for all pelvic 
malignancies at 2.10 (95% CI 1.09-3.67) and for all bladder 
cancers at 3.33 (95% CI 1.44-6.57). In the subgroup analysis 
bladder SPC risk was higher than expected for patients under 
60 years (SIR 6.52; 95%CI 1.3-19; AER 13) and within the first 
5 years of follow up (SIR 2.9 ; 95% CI 0.97-6.95; AER 10). 
Rectal cancer SIR were not significant or close in any of the 
categories. The 5- and 10-year rates of death from SPC were 
1.9 % (95% CI 1.0-3.5) and 9.1% (95% CI 5.2-16) and from any 
cause were 3.2% (95% CI 2-5 ) and 14.4% (95% CI 9.5-21.6). On 
multivariable analysis, older age was associated with 
increased SPC risk (HR 1.05, p=0.021) , all cause mortality 
(HR 1.13, p<0.001) and mortality due to SPC (HR 1.09, 
p=0.014). Smoking status was associated with all cause 
mortality (HR 2.15, p=0.026) and with mortality from second 
malignancy (HR 2.59, p=0.045) 
 
Conclusion: There may be an increased but small risk of 
second pelvic malignancy after prostate brachytherapy. A 
tendency towards a higher risk of bladder SPC after 
brachytherapy was found in the first 5 years of follow-up , 
probably resulting from screening bias . There was no 
significant increased rate of rectal cancer in any of the 
categories. Longer follow up is needed to draw strong 
conclusions.  
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Purpose or Objective: To determine the independent effect 
of additional intraoperative adaptive C-arm cone-beam 
computed tomography (CBCT) planning versus transrectal 
ultrasound (TRUS)-guided interactive planning alone in 
primary permanent I-125 brachytherapy for prostate cancer 
on long term biochemical disease free survival (bDFS). 
 
Material and Methods: All patients with biopsy proven 
T1/T2-stage prostate cancer treated with I-125 
brachytherapy were included in this cohort. Treatments were 
performed with TRUS-guided primary brachytherapy (+/- 
neoadjuvant hormonal therapy (NHT)) in a single institution 
in the period of November 2000 to December 2014. From 
October 2006 onwards, all patients received additional 
intraoperative adaptive CBCT planning for dosimetric 
evaluation and, if indicated, subsequent remedial seed 
placement in underdosed areas (which was performed in 15% 
of all patients). These procedures lasted 1-1.5 hours and 
were performed by a team of 2 radiation oncologists and 2 
therapeutic radiographers. Pre-operative characteristics, 
follow-up PSA and mortality were prospectively registered. 
Patients were stratified into National Comprehensive Cancer 
Network (NCCN) risk groups. Kaplan-Meier analysis was used 
to estimate bDFS (primary outcome), overall survival (OS) 
and prostate cancer specific survival (PCSS) (secondary 
outcomes). Cox-proportional hazard regression was used to 
assess the independent predictive value of CBCT use on 
biochemical failure (BF) (Phoenix definition) and overall 
mortality (OM). 
 
Results: 1623 patients were included. Median follow-up was 
99 months (interquartile range (IQR) 70-115) for TRUS 
patients (n=613) and 51 months (IQR 29-70) for CBCT patients 
(n=1010). BF occurred 203 times and 206 patients died, of 
which 26 due to prostate cancer. For TRUS and CBCT 
patients, estimated 7-year bDFS was 87.2% vs. 93.5% (log 
rank: p=0.04) for low risk patients, 75.9% vs. 88.5% (p<0.001) 
for intermediate risk patients and 57.1 vs. 85.0% (p<0.001) 
for high risk patients. For TRUS and CBCT patients with low, 
intermediate and high risk disease, estimated 7-year OS was 
respectively 86.5% vs. 90.4% (p=0.11), 79.6% vs. 85.1% 
(p=0.30) and 66.4% vs. 84.2% (p=0.01). For TRUS and CBCT 
patients, 7-year PCSS was 96.0% vs. 100% (p<0.0001). After 
Cox regression, CBCT patients had lower rates of BF: HR 0.45 
(95%-CI 0.33-0.61; p<0.0001). Corrected for age, IPSA, 
Gleason grade, T-stage, NHT-status and duration of NHT use, 
year of implantation, activity of the implant and prostate 
volume, CBCT showed to be an independent predictor of BF: 
HR 0.54 (95%-CI 0.33-0.89; p=0.02). CBCT was not an 
independent predictor of OM: HR 0.66 (95%-CI 0.40-1.07; 
p=0.09). 
 
Conclusion: Additional intraoperative adaptive C-arm cone-
beam CT planning in I-125 prostate brachytherapy leads to a 
significant increase in biochemical disease free survival in all 
NCCN risk groups.  
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Purpose or Objective: In adaptive radiotherapy, deformable 
image registration (DIR) is used for contour propagation and 
dose warping. Contour evaluation is visual and qualitative 
and only accurate in high contrast regions. Dose warping 
requires fully spatial and quantitative DIR evaluation 
measures also valid in low contrast regions. While 
